Pharming Acquires Exclusive License to CDZ173, a Late Stage Drug for the Treatment of APDS
-- CDZ173 is in a registration-enabling study for the treatment of APDS, an
ultra-rare, debilitating disease with no approved treatment
-- APDS is treated by ... Lees verder